The Cannabis plant has been used in Europe since antiquity, mostly to make cordage and fabric, but first attracted the attention of European scientists when Napoleon's troops brought back from Egypt intriguing accounts of its psychotropic activity. In 1810, a member of Napoleon's Commission des Sciences et des Arts wrote 1 : "For the Egyptians, hemp is the plant par excellence, not for the uses they make of it in Europe and many other countries, but for its peculiar effects. The hemp cultivated in Egypt is indeed intoxicating and narcotic."
Before long, detailed descriptions of the plant's properties began to appear 2, 3 and Cannabis extracts were introduced to the medical community. An 1848 commentary of the British Pharmacopoeia outlined quite accurately the psychotropic effects of Cannabis and pointed out its merit as an analgesic and antispasmodic 4 : "Numerous observers have described the Indian hemp as producing in the natives of the East, who familiarly use it instead of intoxicating spirits, sometimes a heavy, lazy state of agreeable reverie, from which the individual may be easily roused to discharge any simple duty __ sometimes a cheerful, active state of inebriation causing him to dance, sing and laugh, provoking the venereal appetite, and increasing the desire for food __ and sometimes a quarrelsome drunkenness, leading to acts of violence. During this condition pain is assuaged and spasm arrested. […] On the whole, it is a remedy which deserves a more extensive inquiry than any hitherto instituted."
The inquiry into the active chemical constituents of Cannabis turned out to be more time consuming than expected. Many other plant-derived compounds, such as morphine and atropine, had long been identified when the Cannabis plant finally yielded its active principle, the terpenoid derivative ∆ 9 -tetrahydrocannabinol (THC) 5, 6 (FIG. 1) .
The psychoactive properties of THC were recognized immediately, but the drug's unique chemical structure offered no hints as to its mechanism of action. To complicate matters further, the hydrophobic nature of THC delayed experimentation and indicated that the compound might act by influencing membrane fluidity, rather than by combining with a specific receptor. This impasse was resolved by the development of new classes of potent and selective THC analogue 7 (FIG. 1) , which led eventually to the pharmacological identification of cannabinoid-sensitive sites in the brain 8 . The CB 1 cannabinoid receptor was molecularly cloned from rat brain in 1990 (REF. 9 ) and its immunesystem counterpart, the CB 2 receptor, was identified by sequence homology three years later 10 . These discoveries not only established the mechanism of action of THC, thereby fuelling the development of subtype-selective agonists and antagonists (FIG. 1 ), but they also initiated a hunt for brain-derived cannabinoid ligands. Surprisingly, the first THC-like factor to be isolated was a lipid, rather than the peptide that had been expected on the basis of the precedent set by morphine and the enkephalins. It was identified as the amide of ARACHIDONIC ACID
THE MOLECULAR LOGIC OF ENDOCANNABINOID SIGNALLING
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The endocannabinoids are a family of lipid messengers that engage the cell surface receptors that are targeted by ∆ 9 -tetrahydrocannabinol, the active principle in marijuana (Cannabis). They are made on demand through cleavage of membrane precursors and are involved in various short-range signalling processes. In the brain, they combine with CB 1 cannabinoid receptors on axon terminals to regulate ion channel activity and neurotransmitter release. Their ability to modulate synaptic efficacy has a wide range of functional consequences and provides unique therapeutic possibilities.
, but it is not known whether either of these enzymes is responsible for anandamide synthesis.
The brain contains tiny quantities of N-arachidonoyl-PE (20-40 pmol g -1 ) 23,24 -probably too little to sustain anandamide release for an extended time. The cellular stores of this precursor are replenished by the enzyme N-acyltransferase (NAT), which catalyses the intermolecular passage of an arachidonic acid group from the SN-1 position of PHOSPHATIDYLCHOLINE to the head group of PE 14, 23, 24 (FIG. 3) . In cultures of rat cortical neurons, two intracellular second messengers control NAT activity: Ca 2+ and cyclic AMP. Ca 2+ is required to engage NAT, which is inactive in its absence, whereas cAMP works through protein kinase A-dependent phosphorylation to enhance NAT activity 26 . Although catalysed by separate enzymes, the syntheses of anandamide and its parent lipid are thought to proceed in parallel because Ca 2+ -stimulated anandamide production is generally accompanied by de novo formation of N-arachidonoyl-PE 23, 24 . This small lipid molecule resembled no known neurotransmitter, but it did share structural features with the EICOSANOIDS, mediators of inflammation and pain with various functions in neural communication 12 . Though initially controversial 13 , the signalling roles of anandamide were confirmed by the elucidation of the compound's unique metabolic pathways and the demonstration of its release in the live brain [14] [15] [16] . As the search for THC-like compounds continued, other bioactive lipids were extracted from animal tissues. These include 2-arachidonoylglycerol (2-AG) 17 In this article, I review the synthesis, release and deactivation of the endogenous cannabinoids (also called endocannabinoids). I then outline the properties and distribution of brain CB 1 receptors. Last, I describe the function of the endocannabinoids as local modulators of synaptic activity and their contribution to memory, anxiety, movement and pain. , and imply that a significant fraction of brain 2-AG is engaged in housekeeping functions rather than in signalling.
The place occupied by 2-AG at central intersections of lipid metabolism also complicates efforts to define the biochemical pathway(s) responsible for its physiological synthesis. There is, however, enough information to indicate two possible routes (FIG. 4) . The first begins with the phospholipase-mediated formation of 1,2-diacylglycerol (DAG). This product regulates protein kinase C activity -an important second messenger functionand is a substrate for two enzymes: DAG kinase 33 , which attenuates DAG signalling by catalysing its phosphorylation to phosphatidic acid; and DAG lipase (DGL), which hydrolyses DAG to monoacylglycerol 34 . The fact that drug inhibitors of PLC and DGL block Ca 2+ -dependent 2-AG accumulation in rat cortical neurons indicates primary involvement of this pathway in 2-AG formation 32 . An alternative pathway of 2-AG synthesis begins with the production, mediated by phospholipase A1 (PLA1) 35, 36 , of a 2-arachidonoyl-LYSOPHOSPHOLIPID, which might be hydrolysed to 2-AG by lyso-PLC activity (FIG. 4) . Although there is no direct evidence for this mechanism in 2-AG formation, the high level of PLA1 expression in brain tissue 34, 35 makes it an intriguing target for future investigation. In addition to the phospholipase-operated pathways outlined above, monoacylglycerols can be produced by hormonesensitive lipase acting on triacylglycerols or by lipid phosphatases acting on lysophosphatidic acid. In general, however, these enzymes preferentially target lipids that are enriched in saturated or monounsaturated fatty acids, rather than the polyunsaturated species that would give rise to 2-AG.
Irrespective of its exact mechanism, neuronal 2-AG production can be initiated by an increase in the concentration of intracellular Ca 2+ . In cultures of rat cortical neurons, the Ca 2+ ionophore ionomycin and the glutamate receptor agonist NMDA (N-methyl-Daspartate) stimulate 2-AG synthesis in a Ca 2+ -dependent manner 32, 37 . Likewise, in freshly dissected hippocampal slices, high-frequency stimulation of the SCHAFFER COLLAT-ERALS produces a Ca 2+ -dependent increase in tissue 2-AG content 32 . Importantly, this treatment has no effect on the concentrations of non-cannabinoid monoacylglycerols, such as 1(3)-palmitoylglycerol, which indicates also trigger this process. For example, application of the dopamine D 2 -receptor agonist quinpirole causes an eightfold increase in anandamide outflow in the rat striatum, which is prevented by the D 2 -receptor antagonist raclopride 15 . This response is accompanied by an elevation in tissue anandamide content, indicating that it might be due to a net increase in anandamide formation rather than to extracellular release of preformed anandamide 27 www.nature.com/reviews/neuro R E V I E W S by the role of an intramembranous amino-acid residue (lysine-192) in the binding of anandamide to CB 1 (REF. 39 ), as well as by the finding that certain cannabinoid agonists can approach the receptor by lateral membrane diffusion 40 . Nevertheless, it does not account for two pieces of evidence. First, anandamide is found in incubation media of cells and in brain interstitial fluid, implying that it can overcome its tendency to partition in membranes [14] [15] [16] . Perhaps more importantly, physiological experiments have shown that an endocannabinoid substance does leave postsynaptic cells to activate CB 1 receptors on adjacent axon terminals [41] [42] [43] [44] [45] [46] . This unidentified compound might travel as far as 20 µm from its cell of origin before being eliminated 41 . If endocannabinoids are released from neurons, what is the mechanism of their release? The fact that plasma membranes contain precursor molecules for both anandamide and 2-AG indicates that they could leave the cell as soon as they are formed. Extracellular lipid-binding proteins such as the lipocalins, which are expressed at high levels in the brain 47 , might facilitate this step and help to deliver endocannabinoids to their cellular targets. Although this scenario awaits confirmation, it does mirror what happens in the bloodstream, where anandamide's movements are made possible by its reversible binding to serum albumin 48 .
Deactivation
Two mechanisms cooperate in attenuating endocannabinoid signalling in the brain: carrier-mediated transport into cells and intracellular hydrolysis (FIG. 5) .
Transport. Anandamide and 2-AG can diffuse passively through lipid membranes, but this process is accelerated by a rapid and selective carrier system that is present in both neurons and glial cells 49, 50 .Although it is superficially similar to other transmitter systems, endocannabinoid transport is not driven by transmembrane Na + gradients, indicating that it might be mediated by a FACILITATED DIFFUSION mechanism 49, 50 . In this respect, neural cells seem to internalize anandamide and 2-AG in a manner similar to fatty acids, eicosanoids and other biologically relevant lipids, by using energy-independent carriers. Several lipid-carrier proteins have been molecularly cloned 51 , inspiring optimism that, despite current controversy
, endocannabinoid transporter(s) will eventually be characterized.
Meanwhile, to gain insight into the role of transport in endocannabinoid inactivation, we can rely on an expanding series of pharmacological transport inhibitors. The prototype is AM404, which slows the elimination of both anandamide and 2-AG, magnifying their biological effects 49, 52, 53 (FIG. 6) . This inhibitor has helped to unmask important roles of the endocannabinoid system in the regulation of neurotransmission and synaptic plasticity, but suffers from various limitations, including an affinity for VANILLOID RECEPTORS and susceptibility to enzymatic attack by fatty acid amide hydrolase (FAAH). These limitations have prompted an ongoing search for more selective and stable analogues 54, 55 (FIG. 6) . that 2-AG formation is not due to a generalized increase in the rate of lipid turnover 32 . Furthermore, highfrequency stimulation does not alter hippocampal anandamide concentrations, indicating that the syntheses of 2-AG and anandamide can be independently regulated 32, 37 . In further support of this idea, activation of D 2 receptors -a potent stimulus for anandamide formation in the rat striatum -has no effect on striatal 2-AG concentrations 15, 27 .
Other putative endogenous ligands. Noladin ether is an ether-linked analogue of 2-AG that binds to and activates CB 1 receptors 19 (FIG. 2) . Its pathway of formation has not been characterized, and its occurrence in the normal brain has been questioned 38 . Virodhamine, the ester of arachidonic acid and ethanolamine (FIG. 2) , might act as an endogenous CB 1 antagonist 20 . Its presence in brain tissue has been documented 20 , but is intriguing because this chemically unstable molecule is rapidly converted to anandamide in aqueous environments. The mechanism of its synthesis is unknown, and its deactivation might share anandamide's pathways of uptake and intracellular hydrolysis 20 . Finally, the endogenous vanilloid agonist, N-arachidonoyldopamine, also exhibits affinity for cannabinoid receptors in vitro 21 (FIG. 2) .
Release from neurons
How are endocannabinoids released from cells and how do they reach their targets? Classical transmitters and neuropeptides can diffuse through the water-filled space that surrounds neurons, but hydrophobic compounds such as anandamide and 2-AG tend to remain associated with lipid membranes. One possibility is that endocannabinoids might not leave the cell where they are produced; rather, they could move sideways within the plasmalemma until they collide with membraneembedded CB 1 tightly controls brain concentrations of these compounds 64, 65 , but the functional significance of this regulation is unknown.
FAAH is widely distributed in the rat brain, where it is expressed at high concentrations in cell bodies and dendrites of principal neurons 66, 67 . In the hippocampus, neocortex and cerebellum, FAAH-positive cell bodies are juxtaposed to axon terminals that contain CB 1 receptors, indicating not only that FAAH participates in the inactivation of neurally generated anandamide, but also that this process occurs postsynaptically. This idea can now be tested in FAAH-deficient mice 64 or using selective FAAH inhibitors with long-lasting systemic actions 65 (FIG. 6) .
Monoacylglycerol lipase. The pig brain contains two chromatographically distinct 2-AG-hydrolysing activities 68 , one of which is probably due to the enzyme monoacylglycerol lipase (MGL). The rat brain isoform of this cytosolic serine hydrolase has been characterized both molecularly and morphologically 69 . It has a broad distribution in the central nervous system (CNS), which partially overlaps with that of FAAH; however, whereas FAAH is predominantly found in postsynaptic structures, MGL might be mostly associated with nerve endings 69 . In the hippocampal CA1 field, MGL-positive axon terminals surround cell bodies of pyramidal neurons containing FAAH. This localization could reflect a functional role of presynaptic MGL in terminating RETROGRADE SIGNALLING events mediated by 2-AG (discussed later in this article).
CB 1 signalling
CB 1 is considered to be the most abundant G-proteincoupled receptor in the mammalian brain, and its presence in the neocortex, hippocampus, basal ganglia, cerebellum and brainstem accounts for most of the behavioural actions of cannabinoid drugs 70 . The four symptoms that are often used to define cannabinoid intoxication in the rodent __ hypothermia, rigid immobility, analgesia and decreased motor activity 71 __ are strikingly absent in mice in which the cb1 gene has been deleted by targeted recombination 72, 73 . Aside from its unusually high concentrations in the brain, CB 1 is a standard G i/o -coupled receptor and can initiate signalling events typical of this class of transducing proteins. These include closure of Ca 2+ channels, opening of K + channels, inhibition of adenylyl cyclase activity (with its consequent decrease in cytosolic cAMP concentrations) and stimulation of kinases that phosphorylate tyrosine, serine and threonine residues in proteins. Each of these mechanisms seems to have distinct functions in translating CB 1 -receptor occupation into biological responses.
Cannabinoid agonists inhibit N-and P/Q-type voltage-activated Ca 2+ channels [74] [75] [76] . This effect, which has been suggested to result from a direct interaction of G i/o -protein β−γ subunits with the channels 77 , might underlie CB 1 -mediated depression of transmitter release at GABA (γ-aminobutyric acid) synapses in the CA1 field of the hippocampus 78 and at glutamatergic synapses in the dorsal striatum 79, 80 (FIG. 7a) . Importantly, Fatty acid amide hydrolase. FAAH is an intracellular membrane-bound serine hydrolase that breaks down anandamide into arachidonic acid and ethanolamine [56] [57] [58] [59] (FIG . 5) . It has been molecularly cloned and its catalytic mechanism, which allows it to recognize a broad spectrum of amide and ester substrates, has been elucidated in detail 60 . Particularly notable is FAAH's ability to hydrolyse bioactive fatty amides, which do not bind to any of the known cannabinoid receptors: these include the satiety factor oleoylethanolamide 61 and the anti inflammatory/ analgesic mediator palmitoylethanolamide 62, 63 . FAAH Nature Reviews | Neuroscience mice, but fail to do so in CB 1 -deficient mutants 86 . In addition, low concentrations of CB 1 messenger RNA have been found in many neurons of the cortex that do not contain GABA 92 . CB 1 receptors are also expressed at very high levels throughout the basal ganglia. In the striatum they are localized to three distinct neuronal elements: glutamatergic terminals originating in the cortex 79, 80 , local-circuit GABA interneurons ('fast-spiking' interneurons that do not express CCK-8) 96 and axon terminals of GABA projection neurons ('medium spiny neurons') 97 . Medium spiny neurons project to striatal outflow nuclei, where CB 1 receptors are especially abundant; for example, in the globus pallidus they outnumber dopamine D 1 receptors by a factor of 45 (REF. 97 ).
In the cerebellum, CB 1 is present on excitatory terminals of climbing and parallel fibres (but not on their postsynaptic partners, the Purkinje neurons) as well as on GABA interneurons 70, 93 . Smaller numbers of CB 1 receptors are also found in the thalamus (especially in the anterior dorsal nucleus and habenula), hypothalamus (ventromedial and anterior nuclei), midbrain (periaqueductal grey and superior colliculus), medulla (dorsal vagal complex and rostral ventromedial medulla) and spinal cord (dorsal horn) 70, 93 . Last, CB 1 is expressed in peripheral sensory neurons 98 , where it is localized in cells that express N52, a protein marker of mechanosensitive Aβ fibres 99 .
Another brain receptor?
A few cannabinoid effects persist in CB 1 -null mice, implying that this receptormight not act alone in mediating brain cannabinoid signalling 73, 100 . Although cannabinoid agonists lose their ability to inhibit GABA and glutamate transmission in some brain regions of adult CB 1 -knockout mice 86 , they can still reduce excitatory transmission in the hippocampal CA1 field of these animals 101, 102 . This discrepancy is reinforced by the finding that GABA and glutamate synapses in CA1 respond in different ways to cannabinoid drugs. For example, cannabinoid depression of excitatory currents is blocked by CAPSAZEPINE, whereas depression of inhibitory currents is not 103 . These results make a persuasive case for the existence of a hippocampal cannabinoid-sensitive site that is distinct from CB 1 (sometimes called 'CB 3 '), but other evidence appears to contradict them; for example, in newborn CB 1 -null mice, cannabinoid agonists affect neither GABA nor glutamate transmission 104 . Although this difference could be due to the developmental stage of the preparation used __ adult 101 versus one-week-old mice 104 __ more studies are needed to establish whether the CB 3 site is molecularly distinct from CB 1 . A novel cannabinoid site has also been identified in the vascular endothelium 105 , but seems to be different from CB 3 because it is not antagonized by capsazepine 105 or activated by the CB 1 /CB 2 agonist Win-55212-2 (REF. 106 ).
A local message
Outside the brain, the endocannabinoids are produced on demand and act on cells located near their site of synthesis. For example, they are formed by circulating however, endocannabinoid-mediated suppression of GABA release in hippocampal slices seems primarily to involve N-type Ca 2+ channels 81 . Cannabinoid regulation of voltage-gated K + currents 82 is also implicated in presynaptic inhibition at GABA 83 and glutamate synapses. The latter include PARALLEL FIBRE-Purkinje cell synapses in the cerebellum, as well as synapses in the nucleus accumbens and lateral amygdala [84] [85] [86] (FIG. 7b) . The sensitivity of these responses to PERTUSSIS TOXIN implies that they are mediated by G i/o proteins, but it is still unclear whether transduction is direct (β−γ subunit-mediated) or indirect (second messenger-mediated). Inhibition of cAMP formation does not seem to be involved 85, 86 . On the other hand, cAMP can contribute to the regulation of neuronal gene expression by CB 1 . This process, which is necessary to produce lasting changes in synaptic strength, depends on the recruitment of complex networks of intracellular protein kinases 87 . Two components of these networks, extracellular signal-regulated kinase (ERK) and focal adhesion kinase (FAK), become activated when hippocampal slices are treated with cannabinoid agonists 88, 89 . This activation is mimicked by inhibitors of cAMP-dependent kinase and is lost when the slices are exposed to cell-permeant cAMP analogues, implying that it might result from a decrease in intracellular cAMP concentrations. The involvement of ERK and FAK in synaptic plasticity indicates that these protein kinases could participate in the changes in gene expression and the persistent neural adaptations that accompany cannabinoid administration 90 .
CB 1 distribution
In the rodent and human cortices, CB 1 receptors are primarily found on axon terminals of cholecystokinin-8 (CCK-8)-positive GABA interneurons [91] [92] [93] [94] [95] . This expression pattern dominates the neocortex, hippocampal formation and amygdala, where nerve terminals that form excitatory synapses are ostensibly devoid of CB 1 immunoreactivity 91, 94 . However, there is evidence that excitatory terminals in these regions do contain the receptor; for example, cannabinoid agonists reduce glutamatergic transmission in the amygdala of normal RETROGRADE SIGNALLING The backward movement of signalling molecules from postsynaptic to presynaptic structures, which underlies a variety of short-and long-term changes in synaptic efficacy.
PARALLEL FIBRES
Axons of cerebellar granule cells. Parallel fibres emerge from the molecular layer of the cerebellar cortex towards the periphery, where they extend branches perpendicular to the main axis of the Purkinje neurons and form en passant synapses with this cell type.
PERTUSSIS TOXIN
The causative agent of whooping cough, pertussis toxin causes the persistent activation of G i proteins by catalysing the ADPribosylation of the α-subunit. R E V I E W S interneurons 108 . This indicates that a chemical messenger generated during depolarization of the pyramidal cell must travel backwards across the synapse to induce DSI (FIG. 8) .
There is evidence that this retrograde signalling process involves an endocannabinoid substance, possibly 2-AG. First, CB 1 agonists mimic DSI, whereas CB 1 antagonists block it [41] [42] [43] . Second, DSI is absent in CB 1 -deficient mice 81, 109 . Third, the GABA interneurons that are implicated in DSI express high levels of CB 1 receptors, which are localized to their axon terminals 91 . Fourth, neural activity and Ca 2+ entry stimulate the hippocampal synthesis of 2-AG, but have no effect on anandamide concentrations 32 . Nevertheless, we still don't know whether the endocannabinoid actually crosses back to the presynaptic nerve ending or is produced there by the action of another, unidentified retrograde signal (FIG. 8) .
The fact that DSI is induced in vitro 43 by levels of neural activity that could also be encountered in vivo indicates that this process might have a role in normal brain function. Although this idea is still questioned 110 , various results link DSI to the regulation of hippocampal GAMMA OSCILLATIONS 77 . These network oscillations are coordinated by CB 1 -positive GABA interneurons and are influenced by cannabinoid agonists, raising the possibility that an endocannabinoid substance might modulate their expression 111 and be involved in the organization of hippocampal cell assemblies 112 . Another function of DSI might relate to synaptic plasticity. By weakening GABA-mediated inhibition, DSI could facilitate the induction of long-term potentiation in individual CA1 pyramidal neurons; this might contribute in turn to the formation of 'place fields' or to other forms of hippocampus-dependent learning 113 . Such a cognitive-enhancing action would not contradict the well-known amnesic effects of cannabinoid drugs 114 as the latter might result from a generalized, circuit-independent activation of CB 1 receptors in the hippocampus and other brain areas.
Outside the hippocampus, endocannabinoid-mediated DSI has been shown to occur at interneuronprincipal cell synapses of the cerebellum [115] [116] [117] and probably will soon be discovered elsewhere.
Amygdala: modulation of emotions. CB 1 -bearing interneurons are selectively localized to a subdivision of the amygdala called the basolateral complex 94, 95 , a key station in the neural circuitry that processes emotions and a primary site of cannabinoid analgesia 118 . This localization, and the fact that CB 1 inactivation causes anxiety-like and aggressive responses in rodents 119, 120 , indicate that the endocannabinoid system might influence affective states through changes in the amygdala's efferent activity. This idea is further supported by two findings: first, presentation of anxiogenic stimuli increases anandamide and 2-AG concentrations in the mouse amygdala 121 ; second, FAAH inhibitors exhibit marked anxiolytic-like properties in rats 65 . Locally formed endocannabinoids could modify the amygdala's output in two complementary ways. leukocytes and platelets, and induce vascular relaxation by interacting with cannabinoidreceptors on the surface of neighbouring endothelial and smooth muscle cells 107 . Similar PARACRINE actions are thought to occur in the CNS, where the endocannabinoids might mediate a localized signalling mechanism through which principal neurons modify the strength of incoming synaptic inputs.
Regulation of GABA transmission
Hippocampus: modulation of memory. When a pyramidal neuron in the CA1 field of the hippocampus is depolarized, the inhibitory GABA inputs received by that cell are transiently suppressed. This phenomenon, called depolarization-induced suppression of inhibition (DSI), is initiated postsynaptically by voltage-dependent influx of Ca 2+ into the soma and dendrites of the neuron, but is expressed presynaptically through inhibition of transmitter release from axon terminals of GABA PARACRINE A bioactive substance formed in the body by the action of primary messengers (hormones, neurotransmitters) on their receptors, which produces its effects by acting on cells near its sites of synthesis.
GAMMA OSCILLATIONS Fast (20-80 Hz) synchronous oscillations of brain activity, which are thought to contribute to cognition and movement. (1) engage G-protein α-subunits that (2) cause the opening of K + channels; the resulting membrane hyperpolarization can (3) reduce Ca 2+ entry and inhibit glutamate release. Mechanisms similar to those illustrated above are thought to underlie cannabinoid-mediated inhibition of neurotransmitter release in other brain regions.
www.nature.com/reviews/neuro R E V I E W S to CB 1 -positive interneurons in the hippocampus, with which they share not only a GABA-containing phenotype, but also the ability to discharge high-frequency bursts of action potentials that can inhibit firing in large assemblies of projection cells 124 . Does locally released anandamide gain access to these interneurons? Or does it primarily act on medium spiny cells and their cortical afferents? We don't know yet. But these unanswered questions do not diminish the significance of striatal endocannabinoid signalling, which is further highlighted by the effectiveness of cannabinoid agonists in the symptomatic treatment of LEVODOPA-INDUCED DYSKINESIAS 125 and TOURETTE'S SYNDROME 126 , two disorders with strong striatal underpinnings.
Hindbrain: central analgesia. Beside their actions in the amygdala, cannabinoid agonists can influence the central processing of pain by interacting with CB 1 receptors in the periaqueductal grey 127 , rostral ventromedial medulla 128 and spinal trigeminal nucleus 129 . At each of these sites, CB 1 activation depresses GABA release through a presynaptic mechanism, without causing significant changes in somatic membrane conductances 129, 130 . In the trigeminal nucleus, glycinergic transmission also is inhibited 129 . Painful stimuli elicit anandamide release in the rat periaqueductal grey 16 , and systemic administration of CB 1 antagonists produces HYPERALGESIA in rats and mice 63, 131, 132 . So, noxious stimuli can engage a central analgesic circuit operated by the endocannabinoids, which, working in combination with a parallel mechanism in the periphery, could underlie the analgesic properties of cannabinoid drugs 133 .
Regulation of glutamate transmission
Principal neurons in the hippocampus and cerebellum use endocannabinoids to carry out a signalling process that is analogous in mechanism, but opposite in sign, to DSI, called depolarization-induced suppression of excitation (DSE) 108 . Like DSI, DSE is induced by neuronal depolarization, it consists of a transient depression in neurotransmitter release, and it requires a retrograde endocannabinoid messenger. But unlike DSI, DSE targets glutamatergic rather than GABA axon terminals, and results therefore in reduced excitatory input to the affected cell 108 (FIG. 8) .
Do DSI and DSE occur simultaneously in a single neuron and, if so, how are they coordinated? In cerebellar Purkinje cells, the two opposing phenomena can be elicited by similar stimulation protocols and so are likely to coexist 42 . Although they might be topographically segregated along the longitudinal axis of the neuron, the significance of their coexistence is not known. On the other hand, in the hippocampus, the induction of DSE requires longer periods of depolarization than does DSI, and its magnitude is smaller 104 . This could be explained by the lower sensitivity of glutamatergic terminals to endocannabinoid activation 104 , which would indicate that a switch from DSI to DSE might occur when endocannabinoid concentrations at hippocampal synapses attain a certain threshold value. Again, the role of such a switch, if any, is undefined.
They could depress glutamate release from axon terminals originating in the cortex and other brain regions 86 . In addition, by reducing GABA release from basolateral interneurons, they might disinhibit GABA cells in the adjacent intercalated nuclei and consequently decrease the activity of their postsynaptic targets, the pyramidal neurons in the central nucleus of the amygdala, which constitute the structure's primary efferent pathway 94 .
Basal ganglia: modulation of motor activity. The terminal fields of striatal projection neurons contain the highest densities of CB 1 receptors in the brain. Here, local administration of cannabinoid agonists inhibits GABA release and profoundly affects motor behaviours 122 . Membrane depolarization and dopamine D 2 -receptor activation stimulate striatal anandamide formation 15 , indicating that this endocannabinoid might contribute to the regulation of basal ganglia function. In agreement with this hypothesis, the CB 1 antagonist rimonabant enhances the stimulation of movement that is induced in rats by dopamine agonists 123 , whereas the endocannabinoid transport inhibitor AM404 attenuates this stimulation in a CB 1 -dependent manner 53 .
Anandamide might act at multiple sites in the basal ganglia, including GABA projection neurons, corticostriatal glutamatergic terminals and local-circuit interneurons 79, 96, 97 . Local-circuit interneurons are particularly notable because of their functional resemblance (5) 'CB 3 ' sites on glutamatergic terminals, leading to depolarizationinduced suppression of excitation. Alternatively, the endocannabinoid might not actually cross back to the presynaptic nerve ending, but could be produced in situ by the action of another, unidentified retrograde signal.
R E V I E W S
Other neurotransmitters
The ability of cannabinoid agonists to inhibit the release of neurotransmitters in the CNS is not restricted to glutamate and GABA 136 . A particularly convincing case has been made for acetylcholine, the release of which is reduced by cannabinoids both in vitro and in vivo, and is enhanced by inactivation of CB 1 receptors [136] [137] [138] . Acetylcholine release in the neocortex and hippocampus facilitates learning and memory, so disruption of this facilitatory process might contribute to the detrimental effects of cannabinoid drugs on cognition. Cannabinoids also reduce the release of the biogenic amines noradrenaline and serotonin 136 , and the neuropeptide CCK-8 (REF. 139 ). Analogous, but as yet unknown, actions on peptide release in the hypothalamus might underlie the central involvement of the endocannabinoid system in the secretion of stress hormones and regulation of appetite
.
Enduring inhibitions
Basal ganglia: a role in habit formation? High-frequency stimulation of cortical fibres that innervate the striatum leads to a form of persistent synaptic plasticity called long-term depression (LTD) 140 . Like its hippocampal counterpart, striatal LTD is induced when Ca 2+ enters the somatodendritic compartment of projection neurons, and is expressed as a decrease in glutamate release from axon terminals of corticostriatal fibres 141 . These analogies with DSI are suggestive of an endocannabinoiddependent process, an idea that has been confirmed experimentally 44 . Striatal LTD is absent in CB 1 -deficient mice and is blocked by the CB 1 antagonist rimonabant; moreover, it is induced in a CB 1 -dependent manner by anandamide or AM404 (REF. 44) (FIG. 9a) .
A similar form of endocannabinoid-dependent LTD can be produced by low-frequency stimulation of cortical fibres that innervate the nucleus accumbens 45 . Despite differences in induction protocols in vitro __ one is produced by high-frequency 44 , the other by low-frequency, stimulation 45 __ striatal and accumbal LTD could serve complementary functions. For example, they might both contribute to habit formation, a type of striatumdependent learning that underlies the development of motor skills and is implicated in the pathogenesis of drug addiction 142 . Notably, cannabinoid drugs provoke in rats a relapse to drug-seeking behaviour after prolonged periods of abstinence, whereas CB 1 antagonists attenuate the relapse induced by drug-associated cues 143, 144 . These findings have provided the rationale for current clinical trials of rimonabant as a treatment for alcohol and tobacco addiction
Hippocampus: a role in cognition? In the hippocampal CA1 field, stimulation protocols that cause long-term potentiation at excitatory synapses onto pyramidal neurons simultaneously produce LTD at adjacent inhibitory synapses (I-LTD) 46 . Like striatal LTD, I-LTD might be endocannabinoid-mediated, but its molecular mechanism seems to be remarkably different. According to a current model, glutamate released from excitatory terminals activates metabotropic receptors on dendrites Inhibition of glutamatergic neurotransmission by cannabinoid agonists has been documented in a variety of brain structures besides the hippocampus and cerebellum. These include the prefrontal cortex 134 , amygdala 86 , nucleus accumbens 85 , striatum 79 and substantia nigra pars reticulata 135 . Whether such effects reflect the existence of regional DSE-like phenomena is an important question that remains to be addressed. concentrations produced in postsynaptic spines of striatal medium spiny neurons after the stimulation could trigger anandamide (AEA) formation, which in turn might induce LTD by engaging CB 1 cannabinoid receptors on glutamatergic axon terminals. b | High-frequency stimulation of glutamatergic Schaffer collaterals in the hippocampus elicits a prolonged reduction of GABA (γ-aminobutyric acid) release that might be mediated by 2-arachidonoylglycerol (2-AG). This heterosynaptic form of plasticity, called inhibitory-LTD (I-LTD), is induced when glutamate activates metabotropic receptors (mGluR) on pyramidal neurons, eliciting 2-AG formation through the diacylglycerol lipase (DGL) pathway. 2-AG might then travel sideways to engage CB 1 receptors on contiguous terminals of GABA interneurons, producing I-LTD.
Box 2 | Addicted to food
Although it is well established that marijuana smokers eat more marshmallows than they should, exactly why this occurs is still quite mysterious. However, a few facts seem to be clear 150 . Cannabinoid agonists stimulate food intake in partially fed animals. This effect is probably due to the activation of CB 1 receptors and is accompanied by enhanced food palatability. Moreover, CB 1 antagonists such as rimonabant reduce food intake and body weight in animals. Last, feeding status and feeding-regulating hormones such as leptin can affect endocannabinoid synthesis in the hypothalamus 151 , as well as in intestinal tissue 152 . The neural substrates of these actions have not been elucidated, but their therapeutic potential is under study. The cannabinoid agonist THC (dronabinol, Marinol) has been approved by the US Food and Drug Administration for the treatment of anorexia associated with AIDS, and the antagonist rimonabant is in advanced clinical development for the treatment of obesity. In a proof-of-concept trial (Phase II), which was recently completed, the drug produced a marked reduction of body weight in obese patients; after four months of treatment, patients taking rimonabant lost 4.5 kg, whereas those taking placebo lost only 1 kg. Larger trials (Phase III) are now underway in the United States and Europe to compare the effects of rimonabant and placebo on obesity, hyperlipidaemia and diabetes. Importantly, rimonabant is also under consideration as a treatment for alcohol and tobacco abuse, a reminder of the common neural substrates that underlie drug and food rewards 153 .
from vesicle stores, they are released in a non-synaptic manner and combine with cannabinoid receptors located near their sites of synthesis.
Despite this progress, many crucial pieces of the endocannabinoid puzzle are still missing. For example, we need to map the neuronal circuits that produce anandamide and 2-AG, and this requires in turn the molecular characterization of the synthetic enzymes involved. We also need to understand how classical neurotransmitters and drugs of abuse interact with these circuits, and to explore the functional consequences of such interactions. Last, but not least, we must continue to develop selective pharmacological tools that target not only the different cannabinoid receptor subtypes, but also the mechanisms of endocannabinoid synthesis and deactivation. Although these tasks are far from trivial, what is already known about the endocannabinoid system indicates that they are well worth pursuing.
of pyramidal neurons, which in turn stimulates 2-AG formation through the DGL pathway. The newly formed endocannabinoid can then depress GABA release by engaging CB 1 receptors on inhibitory nerve endings 46 (FIG. 9b) . How this long-lasting disinhibitory process interacts with other forms of endocannabinoiddependent plasticity and contributes to the overall effects of cannabinoids on hippocampus-dependent learning will surely be the object of future discussion and experiments.
Missing pieces
A decade of research in the biology of the endocannabinoid system has led to a series of exciting discoveries. We have learned that the brain contains multiple endocannabinoid lipids, and that neurons produce them using membrane constituents as starting material. We have also discovered that these lipids behave differently from traditional transmitters. Rather than being secreted
